Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Senn

Showing results (131-140 of 193) with videos related to

Pageof 20
Sort By:
Wiener Klinische Wochenschrift|September 18, 1981
[Therapeutic strategies in the treatment of breast cancer (author's transl)]H Huber, C Gattringer, K Grünewald, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 21, 2007
Soraprazan: setting new standards in inhibition of gastric acid secretionW A Simon, M Herrmann, T Klein, et al.
Deutsche Medizinische Wochenschrift (1946)|July 5, 1985
[Therapeutic results in spinal tumor metastases involving neurologic deficit]C Eugster, W F Jungi, A Benini, et al.
British Journal of Cancer|February 2, 2006
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancerG Fürstenberger, R von Moos, R Lucas, et al.
The Journal of Biological Chemistry|May 9, 2001
Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistanceR A Mooney, J Senn, S Cameron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1993
Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate?M Castiglione-Gertsch, S Pampallona, M Varini, et al.
Drug Discovery Today|November 8, 2016
Defining drug response for stratified medicineMike Lonergan, Stephen J Senn, Christine McNamee, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 24, 2001
Risk-adapted therapy for clinical stage I-II Hodgkin's disease: 7-years results of radiotherapy alone for low-risk disease, and ABVD and radiotherapy for high-risk diseaseR G MacKenzie, E Franssen, R Wong, et al.
Schweizerische Medizinische Wochenschrift|December 3, 1983
[Deleterious course in tumor patients with ectopic ACTH secretion and secondary Cushing's syndrome]E E Holdener, W G Tenschert, P U Heitz, et al.
European Journal of Epidemiology|May 23, 2016
Statistical tests, P values, confidence intervals, and power: a guide to misinterpretationsSander Greenland, Stephen J Senn, Kenneth J Rothman, et al.
Pageof 20

Showing results (131-140 of 193) with videos related to

Sort By:
Pageof 20
Wiener Klinische Wochenschrift|September 18, 1981
[Therapeutic strategies in the treatment of breast cancer (author's transl)]H Huber, C Gattringer, K Grünewald, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 21, 2007
Soraprazan: setting new standards in inhibition of gastric acid secretionW A Simon, M Herrmann, T Klein, et al.
Deutsche Medizinische Wochenschrift (1946)|July 5, 1985
[Therapeutic results in spinal tumor metastases involving neurologic deficit]C Eugster, W F Jungi, A Benini, et al.
British Journal of Cancer|February 2, 2006
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancerG Fürstenberger, R von Moos, R Lucas, et al.
The Journal of Biological Chemistry|May 9, 2001
Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistanceR A Mooney, J Senn, S Cameron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1993
Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate?M Castiglione-Gertsch, S Pampallona, M Varini, et al.
Drug Discovery Today|November 8, 2016
Defining drug response for stratified medicineMike Lonergan, Stephen J Senn, Christine McNamee, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 24, 2001
Risk-adapted therapy for clinical stage I-II Hodgkin's disease: 7-years results of radiotherapy alone for low-risk disease, and ABVD and radiotherapy for high-risk diseaseR G MacKenzie, E Franssen, R Wong, et al.
Schweizerische Medizinische Wochenschrift|December 3, 1983
[Deleterious course in tumor patients with ectopic ACTH secretion and secondary Cushing's syndrome]E E Holdener, W G Tenschert, P U Heitz, et al.
European Journal of Epidemiology|May 23, 2016
Statistical tests, P values, confidence intervals, and power: a guide to misinterpretationsSander Greenland, Stephen J Senn, Kenneth J Rothman, et al.
Pageof 20